Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Status:
Withdrawn
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy, safety and tolerability of a combination
of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive
breast cancer.